Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|5|2|102-108

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.5, Iss.2, 2016-03, pp. : 102-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody

By Smith Deborah A.  

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 215-227

Adis International

Access to resources Recommend Favorite

Mepolizumab: 240563, Anti-IL-5 Monoclonal Antibody - GlaxoSmithKline, Anti-Interleukin-5 Monoclonal Antibody - GlaxoSmithKline, SB 240563

By Adis International Limited  

Drugs in R&D, Vol. 9, Iss. 2, 2008-01 ,pp. : 125-130

Adis International

Access to resources Recommend Favorite

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 188-195

John Wiley & Sons Inc

Access to resources Recommend Favorite

Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 2, 2016-03 ,pp. : 150-161

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite